PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

Rhea-AI Summary

PolyPid Ltd. (Nasdaq: PYPD) announced that data from its Phase 2 clinical trial of D-PLEX₁₀₀ for preventing surgical site infections in elective colorectal surgery will be presented at the ASM Microbe 2022 conference on June 9-13, 2022. The study evaluates D-PLEX₁₀₀ alongside standard infection prophylaxis. Dr. Judith Steenbergen will present findings on the impact of the doxycycline-eluting formulation. PolyPid's D-PLEX₁₀₀ is a lead candidate in Phase 3 trials, targeting soft tissue infections.

Positive

• D-PLEX₁₀₀ successfully demonstrated efficacy in Phase 2 trials.
• Presentation at ASM Microbe 2022 showcases the company's commitment to addressing surgical site infections.
• D-PLEX₁₀₀ is advancing to Phase 3 trials, indicating progress toward market readiness.

Negative

• None.

Phase 2 clinical data on the efficacy of D-PLEX₁₀₀ in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation

PETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that data from a previously completed Phase 2 clinical trial of D-PLEX₁₀₀ will be highlighted in a presentation at the upcoming American Microbiology Society (ASM) Microbe 2022, being held on June 9-13, 2022, in Washington, D.C.

The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation,’ evaluates the effect of D-PLEX₁₀₀ in combination with surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The data will be presented by Judith Steenbergen, Ph.D., President of Scientific and Medical Affairs Consulting (SMAC). The abstract will be available on https://www.polypid.com/ following the presentation.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate Contact:

PolyPid Ltd.
Dikla Czaczkes Akselbrad
EVP & CFO
Tel: +972-747195700

Investor Contact:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Nechama Feuerstein
FINN Partners
551-444-0784
Nechama.Feuerstein@finnpartners.com

 

FAQ

What are the results of the Phase 2 clinical trial for D-PLEX100 presented by PolyPid?

The Phase 2 trial results showed that D-PLEX100 effectively reduces surgical site infections when used with standard prophylaxis.

When will the D-PLEX100 trial results be presented?

The results will be presented at the ASM Microbe 2022 conference from June 9-13, 2022.

What is the next step for D-PLEX100 after the Phase 2 trial?

D-PLEX100 is progressing to Phase 3 clinical trials for further evaluation.

How does D-PLEX100 work in preventing infections?

D-PLEX100 utilizes a doxycycline-eluting formulation to target incisional microenvironments and reduce infections.

What is the significance of the ASM Microbe 2022 presentation for PolyPid?

The presentation highlights PolyPid's advancements and potential market impact in the field of surgical infection prevention.